Plain English Summary
Background and study aims
Smoking is a leading cause of numerous diseases including lung cancer, chronic obstructive pulmonary (lung) disease, and atherosclerotic cardiovascular (heart) disease. Reducing the negative health impacts of smoking is a clear public health priority and has led to a series of initiatives to persuade people not to smoke. Despite these efforts, smoking rates in adult populations worldwide remain at 15%-25%. Cigarette smoke is a mixture of more than 5,600 identified chemicals and some of these chemicals contribute to the harmful effects of smoking. Exposure to them can be evaluated by measuring the levels of these chemicals in urine. Nicotine, a chemical found naturally in tobacco leaf and which transfers into cigarette smoke, is mainly responsible for the addictive properties of cigarette smoking. However, it is not the nicotine but many of the other chemicals that are thought to be responsible for the harmful effects of smoking. Although many smokers attempt to quit smoking, few succeed without help. Nicotine replacement therapy (NRT), first introduced in 1978, replaces the nicotine from cigarettes and is thought to assist subjects in stopping smoking by reducing cravings, symptoms of withdrawal and mood changes. Examples of NRT include nicotine patches, gums and, more recently, sprays. In general, the delivery of nicotine from NRT products does not closely match that of cigarettes and this might explain the relatively poor effectiveness of NRT products as aids to quitting smoking. Next Generation Products (NGPs) are nicotine-delivering devices that can be broadly categorized as either tobacco heating products (THPs) or electronic inhalable vapour products (e-cigarettes). THPs are electronic devices that heat tobacco, typically to temperatures lower than 350°C, rather than combusting it. Due to this lack of combustion, far fewer chemicals are formed but nicotine is still released and can be inhaled. THP sticks look similar to a cigarette, including a filter section at the mouth end of the tobacco stick. Less is known about the properties of THPs compared to e-cigarettes. However, a study of the chemicals found in the vapour from a THP when “smoked” on a smoking machine revealed significant reductions in the levels of many chemicals when compared to those found in cigarette smoke. The THP vapour has also been found to contain significant levels of nicotine. The aim of this study is to examine the exposure to cigarette smoke chemicals in smokers who switch from conventional cigarettes to THPs.
Who can participate?
People aged 23 and 55 who smoke 10 to 30 cigarettes per day
What does the study involve?
The study involves staying in a research clinic for a period of up to 8 days. For the first two days, participants continue to smoke cigarettes and their urine is collected to measure the levels of chemicals. Daily samples of blood and breath are also collected for tests. For the following 5 days participants are randomly allocated to either continue smoking cigarettes, switch to using a THP (either a commercially available THP or a new THP that is being developed), or quit using any tobacco products. Urine and blood/breath samples are also collected during this time. Participants in the tobacco use groups then stay in the clinic for a further day so blood samples can be taken to test for nicotine levels when they use a single tobacco product under controlled conditions.
What are the possible benefits and risks of participating?
The benefits include being involved in research assessing whether a novel tobacco product may reduce the impact of tobacco use on a smoker and having access to smoking cessation advice. Participants also receive a medical assessment before entering the study, which may help them to understand more about certain aspects of their general health.
Where is the study run from?
1. Hakata Clinic (Japan)
2. Fukuoka Mirai Hospital Clinical Research Center (Japan)
When is the study starting and how long is it expected to run for?
August 2016 to June 2017
Who is funding the study?
British American Tobacco (Investments) Limited (UK)
Who is the main contact?
Dr Ian Fearon
Dr Ian Fearon
British American Tobacco (Investments) Ltd
Regents Park Road
+44 (0)2380 588641
A randomised, controlled, multi-centre open-label study in healthy Japanese subjects to evaluate the effect on biomarkers of exposure of switching from a conventional combustible cigarette to the glo tobacco heating product
There will be significant reductions in biomarkers of exposure to cigarette smoke toxicants in smokers who switch from smoking conventional cigarettes to using tobacco heating products.
the Hakata Clinic Institutional Review Board (IRB), 16/12/2016, ref: 1684CP
Two-centre randomised longitudinal controlled interventional study
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet
Participants will be randomised either to:
1. Remain smoking a conventional (control) cigarette (mentholated or non-mentholated) for 5 days
2. Switch to using a developmental tobacco heating product (mentholated or non-mentholated) for 5 days
3. Switch to using a commercially-available tobacco heating product for 5 days
4. Cease the use of any tobacco products for 5 days
After entering the clinic, subjects will smoke regular cigarettes ad libitum and up to a maximum amount of 120% of their usual daily cigarette consumption, for a baseline period of 2 days. After this period and according to the randomisation, subjects will either remain smoking for the next 5 days or will switch to using a tobacco heating product or refrain from using any tobacco products, also for 5 days. After this period, subjects in all the tobacco-use groups will remain in the clinic for a further day for a single-use nicotine pharmacokinetic sampling period. After the study, subjects will be followed-up after a period of 5-7 days.
Primary outcome measures
1. Within-group changes in urinary biomarkers of exposure to cigarette smoke toxicants (TNeq, total NNAL, total NNN, 3-HPMA, HMPMA, S-PMA, MHBMA, CEMA, 4-ABP, o-Tol, 2-AN, 1-OHP, HEMA, AAMA and GAMA), measured in daily 24h urine collections (2 baseline days and 5 product use days)
2. Within-group changes in exhaled breath CO (measured daily in exhaled breath using a CO meter), urinary 8-Epi-PGF2α Type III (measured daily from a urine sample) and white blood cell count (performed daily on a sample of venous blood)
Secondary outcome measures
1. Between-group differences in urinary biomarkers of exposure to cigarette smoke toxicants (TNeq, total NNAL, total NNN, 3-HPMA, HMPMA, S-PMA, MHBMA, CEMA, 4-ABP, o-Tol, 2-AN, 1-OHP, HEMA, AAMA and GAMA), measured in daily 24h urine collections (2 baseline days and 5 product use days)
2. Between-group differences in exhaled breath CO (measured daily in exhaled breath using a CO meter), urinary 8-Epi-PGF2α Type III (measured daily from a urine sample) and white blood cell count (performed daily on a sample of venous blood)
3. Plasma nicotine pharmacokinetic parameters (Tmax, Cmax and AUC0-tlast), measured in venous blood samples taken at -5, 1, 3, 4, 5, 6, 7, 10, 15, 30, 60, 120, and 240 minutes relative to the first puff on a single cigarette/THP consumable
4. Subjects' satisfaction with the study products, assessed using a single-item questionnaire at the end of all study procedures
5. Safety profile, assessed at the end of the study period by examining adverse event record and also by vital signs, physical examination, ECG, lung function test, blood and urine tests and a pregnancy test (female subjects only)
Overall trial start date
Overall trial end date
Participant inclusion criteria
1. Subjects will be males or females of Japanese origin and between 23 and 55 years of age, inclusive
2. Subjects will have a body mass index (BMI) between 17.6 and 32.0 kg/m2, inclusive; a body weight exceeding 50 kg (males) or 40 kg (females)
3. Subjects will be in good health, as judged by the PI or designee based on medical history, physical examination, vital signs assessment, 12-lead ECG, clinical laboratory evaluations and lung function tests
4. Subjects will have given their written informed consent to participate in the study and will have agreed to abide by the study restrictions
5. Subjects must demonstrate the ability to comprehend the Informed Consent Form (ICF), be able to communicate well with the PI or their appropriately qualified designee, understand and comply with the requirements of the study, and be judged suitable for the study in the opinion of the PI or their appropriately qualified designee
6. Subjects will be willing to refrain from consuming alcohol within 72 hours prior to Screening and Admission
7. Subjects will be willing to refrain from consuming cruciferous vegetables, and grilled, fried or barbequed food, and avoid being in the presence of the cooking of cruciferous vegetables, and grilled, fried or barbequed food for 48 hours prior to Admission. Subjects will also be willing to avoid food containing poppy seeds for 3 days before both screening and Admission
8. Subjects will be regular smokers of factory-made cigarettes whose chosen brand is within the ISO tar bands 6 mg to 8 mg
9. Subjects will have smoked their chosen brand for a minimum of 6 months and will have smoked for at least 3 consecutive years prior to Screening
10. Subjects will typically smoke at least 10 and a maximum of 30 cigarettes per day and must have a urine cotinine level >200 ng/mL and an exhaled breath CO level >10 ppm at Screening.
11. Subjects will be willing to use the study products (comparator cigarette or THP product) and smoke only the products provided to them during clinical confinement, or to abstain from smoking if assigned to the cessation arm
Target number of participants
Participant exclusion criteria
1. Male subjects who do not agree, or whose partners of childbearing potential do not agree, to use a barrier method of contraception (i.e., a condom with spermicide) in addition to a second highly effective method of contraception used by their female partners or to refrain from donating sperm from Admission (Day -1) until the end of the safety Follow-up period (5-7 days after Discharge)
2. Female subjects of childbearing potential who do not agree to use a highly effective method of birth control in conjunction with male barrier method contraception (i.e. a condom with spermicide) from the time of signing the ICF until the end of the safety Follow-up period (5-7 days after Discharge)
3. Female subjects who are pregnant or breastfeeding. This will be confirmed at Screening and Admission. Any female subject who becomes pregnant during this study will be withdrawn
4. Subjects who have donated ≥400 mL of blood within 90 days prior to Admission; plasma in the 7 days prior to Admission; or platelets in the 6 weeks prior to Admission
5. Subjects who have an acute illness (e.g. upper respiratory tract infection, viral infection, etc.) requiring treatment within 4 weeks prior to Admission
6. Subjects who have regularly used any nicotine or tobacco product other than commercially manufactured filter cigarettes within 14 days of Screening
7. Subjects who are self-reported non-inhalers (smokers who draw smoke from the cigarette into the mouth and throat but who do not inhale). Subjects who are observed as non-inhalers at Admission by the clinic staff will be excluded
8. Subjects who, prior to enrolment, are planning to quit smoking in the next 12 months. All subjects will be informed that they are free to quit smoking and withdraw from the study at any time. Any subject who decides to quit smoking will be directed to appropriate stop smoking services
9. Subjects who have a significant history of alcoholism or drug/chemical abuse within 24 months prior to Screening, as determined by the PI
10. Subjects who have a positive urine drugs of abuse screen at Screening or Admission; or a positive alcohol breath test at Screening or Admission
11. Subjects who have serum hepatitis; are carriers of the hepatitis B surface antigen (HBsAg); are carriers of the hepatitis C antibody; have a positive result for the test for human immunodeficiency virus (HIV) antibodies; or have syphilis
12. Subjects who have used prescription or over-the-counter (OTC) bronchodilator medication (e.g. inhaled or oral β-adrenergic agonists) to treat a chronic condition within the 12 months prior to Admission
13. Subjects who have received any medications or substances (other than tobacco) which interfere with the cyclooxygenase pathway (e.g. anti-inflammatory drugs including aspirin and ibuprofen) within 14 days prior to Admission; or are known to be strong inducers or inhibitors of cytochrome P450 (CYP) enzymes within 14 days or 5 half-lives of the drug (whichever is longer) prior to Admission
14. Subjects who perform strenuous physical activity (exceeding the subject’s normal activity levels) within 7 days prior to Screening or Admission
15. Subjects who are unable to communicate effectively with the PI/study staff (i.e. language problem, poor mental development, or impaired cerebral function)
16. Subjects who are unwilling or unable to comply with the study requirements
17. Employees and immediate relatives of the tobacco industry and the clinical site
18. Subjects who are still participating in another clinical study (e.g. attending Follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical entity) in the past 3 months prior to first product use
19. Subjects who have any clinically relevant abnormal findings on the physical examination, medical history, ECG, lung function tests (forced expiratory volume after 1 second [FEV1]/forced vital capacity [FVC] >0.7 at post-bronchodilator spirometry, post-bronchodilator FEV1 >80% predicted value, and post-bronchodilator FVC >80% predicted value) or clinical laboratory panel, unless deemed not clinically significant by the PI or their appropriately qualified designee
20. Subjects who have, or who have a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological or other major disorder that, in the opinion of the PI or their appropriately qualified designee, would jeopardise the safety of the subject or impact on the validity of the study results
21. Subjects who have previously been diagnosed with any form of malignancy
22. Subjects who have any clinically significant abnormal laboratory safety findings at Screening and prior to first product use, as determined by the PI (1 repeat assessment is acceptable)
23. Subjects who have previously taken part in or withdrawn from this study
24. Subjects who, in the opinion of the PI, should not participate in this study
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Random Square 5-7th FL 6-18, Tenyamachi Hakata-ku
Trial participating centre
Fukuoka Mirai Hospital Clinical Research Center
3-5-1, Kashiiteriha Higashi-Ku
British American Tobacco (Investments) Ltd
Regents Park Road
+44 (0)2380 588641
British American Tobacco (Investments) Limited
Funding Body Type
private sector organisation
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Data from this study will be published in peer-reviewed scientific journals when the study has completed.
IPD sharing plan
The datasets generated and/or analysed during the current study are available from Dr Ian Fearon
(firstname.lastname@example.org) on reasonable request.
Intention to publish date
Participant level data
Available on request
Results - basic reporting